IASLC-ACLC 2022 - IASLC Asia Conference on Lung Cancer 2022
Oct 27 - Oct 29, 2022 | NaraJapan
LARVOL is not affiliated with IASLC Asia Conference on Lung Cancer 2022 and all trademarks, logos, and brand names are property of their respective owners
Showing 6 abstracts linked to Trials
Afatinib + Bevacizumab vs Afatinib Alone as First Line Treatment of Patients with EGFR Mutated NSCLC: Subgroup Analysis of a Randomized, Phase II Study: AfaBev-CS
Tepotinib in Asian Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping
Efficacy and Intracranial Activity of Tepotinib in Japanese Patients with MET Exon 14 Skipping NSCLC (VISION)
A Phase Ib Study of AK112, a PD-1/VEGF Bispecific Antibody, in Combination with Etoposide and Carboplatin in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Phase II Study of S-1 and Cisplatin with Concurrent Thoracic Radiotherapy Followed by Durvalumab for Unresectable, Locally Advanced Non-Small-Cell Lung Cancer in Japan (SAMURAI Study)
CRESTONE: Initial Efficacy and Safety of Seribantumab in Solid Tumors Harboring NRG1 Fusions